<i>In Situ</i> Formed Z-Scheme Graphdiyne Heterojunction Realizes NIR-Photocatalytic Oxygen Evolution and Selective Radiosensitization for Hypoxic Tumors.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36445074.
- Also identified by DOI 10.1021/acsnano.2c09169.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Photon radiotherapy is a common tool in the armory against tumors, but it is limited by hypoxia-related radioresistance of tumors and radiotoxicity to normal tissues. Here, we constructed a spatiotemporally controlled synergistic therapy platform based on the heterostructured CuO@Graphdiyne (CuO@GDY) nanocatalyst for simultaneously addressing the two key problems above in radiotherapy. First, the <i>in situ</i> formed Z-scheme CuO@GDY heterojunction performs highly efficient and controlled photocatalytic O<sub>2</sub> evolution upon near-infrared (NIR) laser stimulation for tumor hypoxia alleviation. Subsequently, the CuO@GDY nanocatalyst with X-ray-stimulated Cu<sup>+</sup> active sites can accelerate Fenton-like catalysis of ·OH production by responding to endogenous H<sub>2</sub>O<sub>2</sub> for the selective killing of tumor cells rather than normal cells. In this way, the sequential combination of NIR-triggered photocatalytic O<sub>2</sub> production and X-ray-accelerated Fenton-like reaction can lead to a comprehensive radiosensitization. Overall, this synergism underscores a controllable and precise therapy modality for simultaneously unlocking the hypoxia and non-selectivity in radiotherapy.
Medical subject headings
- Oxygen
- Hydrogen Peroxide